Park Juwon, Bae Eunkyung, Lee Chansu, Yoon Sung-Soo, Chae Yang Seok, Ahn Kwang-Sung, Won Nam Hee
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Tumour Biol. 2010 Dec;31(6):643-50. doi: 10.1007/s13277-010-0081-1. Epub 2010 Sep 4.
Human renal cell carcinoma (HRCC) is characterized by a high level of resistance to all treatment modalities. Therefore, the investigation of global gene expression in HRCC might help understand its biologic behavior and develop treatment strategies. Using cDNA microarray analysis, we initially compared gene expression profiles between HRCCs and adjacent normal tissues, and found that 87 were up-regulated and 127 genes were down-regulated. Next, a subset of genes, twofold differentially expressed, were validated by Northern blotting. Unexpectedly, caveolin-1, a gene reported to be a tumor suppressor gene, was found to be up-regulated in HRCC tissues. Expression level of caveolin-1 in SN12CPM6 (high metastatic clone) was higher than in SN12C (low metastatic clone), and SN12CPM6 was more resistant to doxorubicin (DXR) than SN12C. Caveolin-1 gene was slightly induced in surviving SN12C cells after DXR treatment. Furthermore, SN12CPM6-siCav1 cells, which were transfected with siRNA of cavelon-1 gene, were more sensitive to DXR, compared to SN12CPM6, but reduction of caveolin-1 gene expression did not affect tumor formation in subcapsule of kidney and lung metastasis. On the other hand, induction of caveolin-1 gene affected the production of lung metastasis under anti-cancer drug treatment: the incidence of pulmonary metastasis was significantly lower in SCID mice injected with SN12CPM6-siCav1 cells, and the number of pulmonary nodules decreased significantly (p = 0.0004). The above results together suggest that caveolin-1 may confer a growth advantage to cancer cells during DXR chemotherapy and surviving HRCC cells eventually might develop lung metastasis.
人肾细胞癌(HRCC)的特点是对所有治疗方式都具有高度抗性。因此,研究HRCC中的全局基因表达可能有助于了解其生物学行为并制定治疗策略。我们使用cDNA微阵列分析,首先比较了HRCC与相邻正常组织之间的基因表达谱,发现87个基因上调,127个基因下调。接下来,通过Northern印迹法验证了一组差异表达两倍的基因。出乎意料的是,据报道为肿瘤抑制基因的小窝蛋白-1在HRCC组织中上调。小窝蛋白-1在SN12CPM6(高转移克隆)中的表达水平高于SN12C(低转移克隆),并且SN12CPM6比SN12C对阿霉素(DXR)更具抗性。在DXR处理后,存活的SN12C细胞中轻微诱导了小窝蛋白-1基因。此外,与SN12CPM6相比,用小窝蛋白-1基因的siRNA转染的SN12CPM6-siCav1细胞对DXR更敏感,但小窝蛋白-1基因表达的降低并不影响肾包膜下肿瘤形成和肺转移。另一方面,小窝蛋白-1基因的诱导影响了抗癌药物治疗下肺转移的发生:注射SN12CPM6-siCav1细胞的SCID小鼠肺转移的发生率显著降低,肺结节数量显著减少(p = 0.0004)。上述结果共同表明,小窝蛋白-1可能在DXR化疗期间赋予癌细胞生长优势,存活的HRCC细胞最终可能发生肺转移。